Shweta Maniar Sells 3,782 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) Director Shweta Maniar sold 3,782 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total transaction of $173,518.16. Following the transaction, the director now owns 10,902 shares of the company’s stock, valued at approximately $500,183.76. This trade represents a 25.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

RxSight Price Performance

RXST stock opened at $46.40 on Thursday. The firm’s fifty day simple moving average is $49.00 and its 200-day simple moving average is $52.48. RxSight, Inc. has a 12 month low of $28.88 and a 12 month high of $66.54. The company has a market capitalization of $1.87 billion, a P/E ratio of -55.78 and a beta of 1.19.

Institutional Investors Weigh In On RxSight

Several hedge funds have recently added to or reduced their stakes in RXST. CWM LLC raised its stake in shares of RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after buying an additional 371 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in RxSight by 854.1% during the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after acquiring an additional 521 shares during the period. Quarry LP raised its position in RxSight by 82.3% during the third quarter. Quarry LP now owns 638 shares of the company’s stock valued at $32,000 after acquiring an additional 288 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in RxSight in the third quarter valued at approximately $34,000. Finally, Quest Partners LLC acquired a new position in RxSight in the second quarter valued at approximately $41,000. 78.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Wells Fargo & Company decreased their price objective on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Jefferies Financial Group started coverage on RxSight in a report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price target for the company. Oppenheimer dropped their price target on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Finally, Stifel Nicolaus dropped their target price on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, RxSight currently has a consensus rating of “Buy” and an average target price of $61.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.